B cell aplasia and hypogammaglobulinemia associated with levetiracetam

Levetiracetam (LEV) is a second-generation antiepileptic drug approved for the treatment of several types of epilepsy. We report a 45-year-old female who developed hypogammaglobulinemia and B cell aplasia during LEV treatment. The Naranjo probability score for an adverse drug reaction was 6. After L...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozdemir, Hulya, Sumer, Sua, Karabagli, Hakan, Akdemir, Gokhan, Caliskaner, A. Zafer, Artac, Hasibe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital and Research Centre 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074184/
https://www.ncbi.nlm.nih.gov/pubmed/29313528
http://dx.doi.org/10.5144/0256-4947.2018.09.01.1430
Descripción
Sumario:Levetiracetam (LEV) is a second-generation antiepileptic drug approved for the treatment of several types of epilepsy. We report a 45-year-old female who developed hypogammaglobulinemia and B cell aplasia during LEV treatment. The Naranjo probability score for an adverse drug reaction was 6. After LEV discontinuation, the number of B cells gradually increased and reached normal levels within two months. This case suggests that monitoring of immunoglobulin levels and lymphocyte subsets analysis is important in patients treated with LEV, especially in cases of prolonged infections.

Ejemplares similares